Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clive Harmer

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 18, 2010
Thyroid cancer is rare. ForewordClive Harmer
The Lancet. Oncology|July 27, 2002
Management of thyroid cancerLouiza Vini, Clive Harmer
Nuclear Medicine Communications|August 21, 2004
Thyroid cancer: an overviewMasud Haq, Clive Harmer
Clinical Nuclear Medicine|July 19, 2005
Metastatic thyroid carcinoma causing superior vena caval obstruction diagnosed on I-131 scanKshama Wechalekar, Masud Haq, Clive Harmer, et al.
Clinical Endocrinology|June 20, 2002
Testicular dose and fertility in men following I(131) therapy for thyroid cancerStephen Hyer, Louiza Vini, Mary O'Connell, et al.
The Annals of Thoracic Surgery|December 23, 2006
Prolonged survival due to spontaneous regression and surgical excision of malignant mesotheliomaJohn E Pilling, Andrew G Nicholson, Clive Harmer, et al.
Cancer|May 27, 2003
Long-term results in elderly patients with differentiated thyroid carcinomaLouiza Vini, Stephen L Hyer, Jennifer Marshall, et al.
The Journal of Clinical Endocrinology and Metabolism|October 13, 2006
131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic reviewAllan Hackshaw, Clive Harmer, Ujjal Mallick, et al.
European Journal of Endocrinology|May 11, 2004
Diagnostic 131I whole body scanning after thyroidectomy and ablation for differentiated thyroid cancerHenry Taylor, Stephen Hyer, Louiza Vini, et al.
The Lancet. Diabetes & Endocrinology|December 4, 2018
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trialHakim-Moulay Dehbi, Ujjal Mallick, Jonathan Wadsley, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 18, 2010
Thyroid cancer is rare. ForewordClive Harmer
The Lancet. Oncology|July 27, 2002
Management of thyroid cancerLouiza Vini, Clive Harmer
Nuclear Medicine Communications|August 21, 2004
Thyroid cancer: an overviewMasud Haq, Clive Harmer
Clinical Nuclear Medicine|July 19, 2005
Metastatic thyroid carcinoma causing superior vena caval obstruction diagnosed on I-131 scanKshama Wechalekar, Masud Haq, Clive Harmer, et al.
Clinical Endocrinology|June 20, 2002
Testicular dose and fertility in men following I(131) therapy for thyroid cancerStephen Hyer, Louiza Vini, Mary O'Connell, et al.
The Annals of Thoracic Surgery|December 23, 2006
Prolonged survival due to spontaneous regression and surgical excision of malignant mesotheliomaJohn E Pilling, Andrew G Nicholson, Clive Harmer, et al.
Cancer|May 27, 2003
Long-term results in elderly patients with differentiated thyroid carcinomaLouiza Vini, Stephen L Hyer, Jennifer Marshall, et al.
The Journal of Clinical Endocrinology and Metabolism|October 13, 2006
131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic reviewAllan Hackshaw, Clive Harmer, Ujjal Mallick, et al.
European Journal of Endocrinology|May 11, 2004
Diagnostic 131I whole body scanning after thyroidectomy and ablation for differentiated thyroid cancerHenry Taylor, Stephen Hyer, Louiza Vini, et al.
The Lancet. Diabetes & Endocrinology|December 4, 2018
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trialHakim-Moulay Dehbi, Ujjal Mallick, Jonathan Wadsley, et al.
Pageof 2